Menu

National Cancer Institute Will Stop Funding Nanotechnology Centers

The Centers of Cancer Nanotechnology Excellence were established in 2005 through several phases of funding, which are reported to end next year.

May 20, 2019
Chia-Yi Hou

ABOVE: National Cancer Institute in Maryland
NATIONAL CANCER INSTITUTE

The US National Cancer Institute announced that next year it will stop funding the Centers of Cancer Nanotechnology Excellence, reports Science. The Centers encompasses several research groups at various institutions, including Caltech, the University of California, Los Angeles, Northwestern University, Cornell University, and others, according to its website.

The Centers of Cancer Nanotechnology Excellence (CCNEs) focus on developing nanotechnology for cancer treatment. The end to funding represents a “natural transition” from putting dedicated support into an emerging field to becoming a more mature research field that fits in with other cancer fields, says Piotr Grodzinski of the National Cancer Institute’s (NCI) Nanodelivery Systems and Devices Branch, which oversees the CCNEs, to Science.

The CCNEs started in 2005 as eight research groups in the first phase, nine getting funding in 2010 in the second phase, and six funded in 2015 for the third phase, according to Science. Some experts state that ceasing their funding may negatively affect cancer research and the future possibility for using nanotechnology in treatments because it unlinks the two fields. “You might not see the integration between disciplines,” Michelle Bradbury, a radiologist at Memorial Sloan Kettering Cancer Center where one of the CCNEs is based, tells Science.

September 2019

Our Inner Neanderthal

Ancient secrets in the human genome

Marketplace

Sponsored Product Updates

Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
Atlas Antibodies AB, a leading supplier of advanced research reagents, announced today the introduction of pre-quantified QPrEST™ Protein Standards for absolute quantification of proteins in biological samples such as cell lysate and plasma using liquid chromatography (LC)–mass spectrometry (MS).
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
BIA Separations introduces Cornerstone AAV Process Development Service to accelerate gene therapy production
CORNERSTONE program integrates process development expertise and novel technology to remove development bottlenecks in the manufacture of Gene Therapy Medicinal Products (GTMPs). Portfolio includes novel CIMasphere™ technology for higher yielding processes and safer products in AAV-based programs
Protein Biomarker Discovery and Analysis
Protein Biomarker Discovery and Analysis
Download this application note from Olink Proteomics to learn about the potential of proteomics for accelerating pharmaceutical development and how proteomics offers solutions to common problems facing drug development scientists.
Streamline Beer, Wine, and Food Quality Control and Safety Analyses
Streamline Beer, Wine, and Food Quality Control and Safety Analyses
Download this eBook from Molecular Devices to learn how to conduct high-throughput detection of melamine, detect endotoxin presence using microplates, and analyze beer and wine composition!